NASDAQ$COCP
Cocrystal Pharma Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results for the year ended December 31, 2021, and provided updates on its antiviral pipeline, upcoming milestones and business activities.
Cocrystal Pharma reported no revenues for 2021 compared to $2.0 million in 2020 due to Merck assuming activities and expenses for the influenza A/B collaboration. R&D expenses increased to $8.8 million, and the net loss was $14.2 million, or $0.16 per share. The company's cash position remains strong with $58.7 million.
- Enrollment is underway in Phase 1 trial with antiviral compound CC-42344 for influenza A.
- Plans to initiate first-in-human clinical studies in 2022 with two SARS-CoV-2 protease inhibitors.
- Received extensive comments from the FDA on pre-IND briefing package for CDI-45205.
- Company is well positioned to execute on its strategy with a clean capital structure and sufficient cash balance through 2023.
Headline financials
Revenue & EPS history
Cocrystal Pharma · Revenue · Quarterly
$5.43K
Forward guidance
The Company expects R&D expenses to increase during 2022 due to the advancement of our influenza A program into the clinic and progress with preclinical COVID-19 programs toward clinical development.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
-0.9%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+0.9%
Avg return
30 days after
33%
19 / 58 earnings
Positive
+25.0%
Q3 2024
Best reaction
-33.3%
Q1 2013
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.6% | -11.9% | -21.0% | |
| Q4 2026 | -2.9% | +51.0% | +43.0% | |
| Q3 2025 | +0.0% | -3.9% | +1.9% | |
| Q2 2025 | -1.2% | -8.9% | -6.0% | |
| Q1 2025 | -7.4% | +4.1% | +5.5% | |
| Q4 2024 | +4.1% | +6.5% | +23.6% | |
| Q3 2024 | +25.0% | +17.6% | +8.5% | |
| Q2 2024 | -10.0% | +10.5% | -12.1% | |
| Q1 2024 | +8.1% | +12.7% | +61.8% | |
| Q4 2023 | +0.0% | -1.3% | +4.0% | |
| Q3 2023 | -1.1% | -11.1% | -5.3% | |
| Q2 2023 | +2.1% | -5.9% | -31.1% | |
| Q1 2023 | -3.8% | -13.2% | -3.8% | |
| Q4 2022 | +4.4% | +8.3% | +37.8% | |
| Q3 2022 | +0.0% | -3.3% | -19.5% | |
| Q2 2022 | +0.0% | -8.7% | -23.9% | |
| Q1 2022 | -5.0% | +0.0% | +2.5% | |
| Q4 2021 | +1.7% | -1.7% | -12.1% | |
| Q3 2021 | -2.2% | -9.9% | -22.0% | |
| Q2 2021 | +2.9% | -1.0% | +2.9% | |
| Q1 2021 | +2.7% | +1.8% | +15.0% | |
| Q4 2020 | -5.0% | -2.5% | -24.5% | |
| Q3 2020 | -2.3% | +2.3% | +64.4% | |
| Q2 2020 | -7.3% | -10.5% | -58.6% | |
| Q1 2020 | -2.8% | -1.4% | +30.6% | |
| Q4 2019 | +5.9% | +2.9% | +33.8% | |
| Q3 2019 | -21.0% | -30.6% | -25.8% | |
| Q2 2019 | -10.8% | -14.9% | -34.0% | |
| Q1 2019 | +0.7% | -1.1% | -5.5% | |
| Q4 2018 | +0.7% | -1.1% | -5.5% | |
| Q3 2018 | +6.8% | +42.2% | +91.7% | |
| Q2 2018 | -5.5% | -4.3% | -19.4% | |
| Q1 2018 | +5.0% | -14.5% | -64.4% | |
| Q4 2017 | -2.1% | +10.9% | -30.0% | |
| Q3 2017 | +0.0% | +0.0% | -11.5% | |
| Q4 2016 | +0.0% | +0.0% | -11.5% | |
| Q2 2017 | +0.0% | +0.0% | +52.6% | |
| Q1 2017 | +0.0% | +15.4% | +3.8% | |
| Q3 2016 | +0.0% | -8.2% | -12.2% | |
| Q2 2016 | +4.4% | +0.0% | +11.1% | |
| Q4 2015 | -3.1% | — | — | |
| Q1 2016 | +7.0% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q4 2014 | +16.7% | — | — | |
| Q1 2015 | +16.7% | — | — | |
| Q3 2014 | +0.0% | — | — | |
| Q1 2014 | +12.1% | — | — | |
| Q2 2014 | +12.1% | — | — | |
| Q4 2013 | -3.3% | — | — | |
| Q3 2013 | -21.1% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q4 2012 | -33.3% | — | — | |
| Q1 2013 | -33.3% | — | — | |
| Q3 2012 | +0.0% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro